Cited by 347Coffee research and impactsDementia and Cognitive Impairment ResearchMedicinal Plants and Neuroprotection

The neuroprotective effects of caffeine: A prospective population study (the Three City Study)

Ritchie, K., Carrière, I., de Mendonça, A., Portet, F., Dartigues, J. F., Rouaud, O., Barberger-Gateau, P., Ancelin, M. L.·2007·Neurology

Abstract

OBJECTIVE: To examine the association between caffeine intake, cognitive decline, and incident dementia in a community-based sample of subjects aged 65 years and over. METHODS: Participants were 4,197 women and 2,820 men from a population-based cohort recruited from three French cities. Cognitive performance, clinical diagnosis of dementia, and caffeine consumption were evaluated at baseline and at 2 and 4 year follow-up. RESULTS: Caffeine consumption is associated with a wide range of sociodemographic, lifestyle, and clinical variables which may also affect cognitive decline. Multivariate mixed models and multivariate adjusted logistic regression indicated that women with high rates of caffeine consumption (over three cups per day) showed less decline in verbal retrieval (OR = 0.67, CI = 0.53, 0.85), and to a lesser extent in visuospatial memory (OR = 0.82, CI = 0.65, 1.03) over 4 years than women consuming one cup or less. The protective effect of caffeine was observed to increase with age (OR = 0.73, CI = 0.53, 1.02 in the age range 65 to 74; OR = 0.3, CI = 0.14, 0.63 in the range 80+). No relation was found between caffeine intake and cognitive decline in men. Caffeine consumption did not reduce dementia risk over 4 years. CONCLUSIONS: The psychostimulant properties of caffeine appear to reduce cognitive decline in women without dementia, especially at higher ages. Although no impact is observed on dementia incidence, further studies are required to ascertain whether caffeine may nonetheless be of potential use in prolonging the period of mild cognitive impairment in women prior to a diagnosis of dementia.

Integrity signals

Registry

Crossref · 10.1212/01.wnl.0000266670.35219.0c

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The citation lists haven’t been fetched yet

References 25 · Cited by 347

Authors
Ritchie, K., Carrière, I., de Mendonça, A., Portet, F., Dartigues, J. F., Rouaud, O., Barberger-Gateau, P., & Ancelin, M. L.
Affiliations
  • University of Lisbon (PT)
  • From INSERM U888 (K.R., I.C., F.P., A.d.M., M.L.A.), Montpellier; INSERM U593 (J.F.D., P.B.-G.), Bordeaux University 2; INSERM U708 (O.R.), University of Paris, France; and Department of Neurology and Laboratory of Neurosciences (A.d.M.), University of Lisbon, Portugal.
Venue
Neurology
Published
2007-08-07
Volume
69
Issue
6
Pages
536-545
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2009631046
Cited by
347
References
25
Citations by year
2026: 4 · 2025: 7 · 2024: 13 · 2023: 16 · 2022: 20 · 2021: 18 · 2020: 17 · 2019: 13 · 2018: 20 · 2017: 22 · 2016: 26 · 2015: 23 · 2014: 24 · 2013: 19 · 2012: 25
FWCI
13.21
Type
journal article
Language
en
Open access
closed
Locations
  • Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Coffee research and impacts
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
Keywords
caffeine, neuroprotection, cognitive decline, dementia, older adults, sex differences, verbal memory, visuospatial memory, psychostimulants, mild cognitive impairment
MeSH terms
Aged, Aged, 80 and over, Agnosia, Caffeine, Coffee, Cognition, Cognition Disorders, Dementia, Female, Follow-Up Studies, France, Humans, Male, Memory Disorders, Prospective Studies, Risk Factors, Sampling Studies, Sex Characteristics, Urban Population, Verbal Learning, Cohort Studies, Incidence, Amyloid beta-Peptides, Disease Progression, Neuroprotective Agents, AIDS Arteritis, Central Nervous System, Purinergic P1 Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review